<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00995293</url>
  </required_header>
  <id_info>
    <org_study_id>DOCET_L_02557</org_study_id>
    <nct_id>NCT00995293</nct_id>
  </id_info>
  <brief_title>Taxotere (Docetaxel) New Indication: Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treatment Registration Trial</brief_title>
  <official_title>An Open-label, Randomized, Parallel-group, Multicenter Study of Neoadjuvant Docetaxel(Taxotere®) Plus Cisplatin Plus 5-fluorouracil Versus Neoadjuvant Cisplatin Plus 5-fluorouracil in Patients With Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Primary Objective is to evaluate the progression-free survival after treatment with&#xD;
      docetaxel plus cisplatin plus 5-Fluorouracil (5-FU) (DCF) in comparison with cisplatin plus&#xD;
      5-FU (CF) in patient with locally advanced inoperable SCCHN The Secondary Objective is to&#xD;
      evaluate and compare the clinical response rate both before and after radiotherapy, the local&#xD;
      symptoms, the duration of response, the time to treatment failure, the survival, the toxicity&#xD;
      and the quality of life in the 2 study groups.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 27, 2009</start_date>
  <completion_date type="Actual">January 26, 2018</completion_date>
  <primary_completion_date type="Actual">January 26, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From randomization to any progression event or patient death (follow-up every 3 months 1st year, then every 6 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From randomization to patient death (follow-up every 3 months 1st year, then every 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rates</measure>
    <time_frame>From randomization to any progression event or patient death (follow-up every 3 months 1st year, then every 6 months) and at the end of chemotherapy + end of radiotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>From randomization to any progression event or patient death (follow-up every 3 months 1st year, then every 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>From randomization to any progression event or patient death (follow-up every 3 months 1st year, then every 6 months) and at the end of chemotherapy + end of radiotherapy</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Head and Neck Neoplasms</condition>
  <arm_group>
    <arm_group_label>Docetaxel Cisplatin 5-Fluorouracil (DCF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 cycles of the following products every 3 weeks (unless disease progression/relapse or unacceptable toxicity occured or the patient refused treatment):&#xD;
Docetaxel 60mg/m² on day 1&#xD;
Cisplatin 75mg/m² on day 1&#xD;
5-FU 750mg/m²/day on day 1 to day 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cisplatin 5-Fluorouracil (CF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 cycles of the following products every 3 weeks (unless disease progression/relapse or unacceptable toxicity occured or the patient refused treatment):&#xD;
Cisplatin 75mg/m² on day 1&#xD;
5-FU 750mg/m²/day on day 1 to day 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DOCETAXEL</intervention_name>
    <description>Intravenous</description>
    <arm_group_label>Docetaxel Cisplatin 5-Fluorouracil (DCF)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CISPLATIN</intervention_name>
    <description>Intravenous</description>
    <arm_group_label>Cisplatin 5-Fluorouracil (CF)</arm_group_label>
    <arm_group_label>Docetaxel Cisplatin 5-Fluorouracil (DCF)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FLUOROURACIL</intervention_name>
    <description>Intravenous</description>
    <arm_group_label>Cisplatin 5-Fluorouracil (CF)</arm_group_label>
    <arm_group_label>Docetaxel Cisplatin 5-Fluorouracil (DCF)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Tumor type: Histologically or cytologically proven squamous cell carcinoma of the head&#xD;
             and neck (SCCHN) presenting with locally advanced disease at diagnosis. Primary tumor&#xD;
             sites eligible are: oral cavity, oropharynx, hypopharynx and larynx.&#xD;
&#xD;
          -  Extent of the disease:&#xD;
&#xD;
               -  Patients are required to have at least one measurable lesion.&#xD;
&#xD;
               -  Stage III or IV without evidence of distant metastases, according to the TNM&#xD;
                  staging system. Absence of metastases must be checked by chest X-ray (with or&#xD;
                  without Computed tomography (CT) ), abdominal ultrasound or CT in case of liver&#xD;
                  function test abnormalities, and bone scan in case of local symptoms.&#xD;
&#xD;
               -  Tumor considered as inoperable after evaluation by a multidisciplinary team.&#xD;
                  Reason for inoperability will be reported in the CRF&#xD;
&#xD;
          -  World Health Organization (WHO) performance status 0 or 1&#xD;
&#xD;
          -  Laboratory data:&#xD;
&#xD;
               -  Haematology:&#xD;
&#xD;
          -  Neutrophil count &gt; or = 2.0*10^9/L&#xD;
&#xD;
          -  Platelet count &gt; or = 100*10^9/L&#xD;
&#xD;
          -  Hemoglobin &gt; or = 10 g/dl (6.2 mmol/L)&#xD;
&#xD;
               -  Hepatic function:&#xD;
&#xD;
          -  Total serum bilirubin &lt; or = 1 time the upper normal limit (UNL) of the participating&#xD;
             center&#xD;
&#xD;
          -  Aspartate transaminase (ASAT/SGOT) and Alanine transaminase (ALAT/SGPT) &lt; or = 2.5UNL&#xD;
&#xD;
          -  Alkaline phosphatase &lt; or = 5 UNL&#xD;
&#xD;
          -  Patients with ASAT or ALAT &gt; 1.5UNL associated with alkaline phosphatase &gt;2.5UNL are&#xD;
             not eligible for the study&#xD;
&#xD;
               -  Renal function:&#xD;
&#xD;
          -  serum creatinine &lt; or = 120µmol/L (1.4 mg/dl) if values are &gt;120µmol/L, creatinine&#xD;
             clearance should be &gt; or = 60 ml/min&#xD;
&#xD;
          -  Absence of any psychological, familial, sociological or geographical condition&#xD;
             potentially hampering compliance with the study protocol and follow-up schedule, those&#xD;
             conditions should be discussed with the patient before registration in the trial&#xD;
&#xD;
          -  Patients informed consent form obtained&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Tumors of the nasopharynx, the nasal and paranasal cavities.&#xD;
&#xD;
          -  Previous chemotherapy or radiotherapy for any reason and previous surgery for SCCHN at&#xD;
             time of study entry.&#xD;
&#xD;
          -  Prior treatment within a therapeutic clinical tria within 30 days prior to study entry&#xD;
&#xD;
          -  Concurrent treatment with any other anticancer therapy&#xD;
&#xD;
          -  Chronic treatment (&gt; or = 3 months) with corticosteroids at a daily dose &gt; or = 20mg&#xD;
             methylprednisolone or equivalent.&#xD;
&#xD;
          -  Concomitant use of drugs which could interact with 5-fluorouracil (e.g. cimetidine,&#xD;
             allopurinol, folic or folinic acid, methotrexate and metronidazole)&#xD;
&#xD;
          -  Previous or current malignancies at other sites with the exception of adequately&#xD;
             treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma of the&#xD;
             skin or other cancer curatively treated by surgery and with no evidence of disease for&#xD;
             at least 5 years&#xD;
&#xD;
          -  Symptomatic peripheral neuropathy &gt; or = grade 2 by NCIC-CTG criteria&#xD;
&#xD;
          -  Clinical altered hearing&#xD;
&#xD;
          -  Pregnant, lactating women or of childbearing potential unless adequate&#xD;
&#xD;
          -  with other serious illness or medical condition including but not limited to:&#xD;
&#xD;
               -  unstable cardiac disease despite treatment&#xD;
&#xD;
               -  myocardial infarction within 6 months prior to study entry&#xD;
&#xD;
               -  history of significant neurologic or psychiatric disorders including dementia or&#xD;
                  seizures&#xD;
&#xD;
               -  active uncontrolled infection&#xD;
&#xD;
               -  active peptic ulcer&#xD;
&#xD;
               -  chronic obstructive pulmonary disease requiring hospitalization during the year&#xD;
                  preceding study entry&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mo Chen</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi Administrative Office</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>September 22, 2009</study_first_submitted>
  <study_first_submitted_qc>October 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2009</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

